Cantargia obtains patent in USA for the antibody CAN03
Cantargia AB today announces that the United States Patent and Trademark Office (USPTO) has granted the company’s patent application 15/501,710 directed to the antibody CAN03, which is of relevance for Cantargia’s CANxx project. The patent number is US 10,100,119 and the patent is valid until 2035.
Cantargia develops antibody-based pharmaceuticals against the interleukin 1 receptor accessory protein (IL1RAP). The lead project CAN04 is currently in clinical development for treatment of non-small cell lung cancer and pancreatic cancer. A second project, CANxx, is in preclinical phase with the aim to develop an antibody against IL1RAP for treatment of autoimmune/inflammatory diseases. One antibody, CAN03, originally developed as a backup candidate for CAN04, modifies IL1RAP signaling in a unique way and has additionally demonstrated interesting IL-33 blocking properties. CAN03 is included in the CANxx discovery program.
The USPTO has now notified Cantargia that they have issued a patent covering the CAN03 antibody. This follows a previous communication from the company in May 2018, that the USPTO issued a Notice of Allowance.
“We are starting to build a patent portfolio for our CANxx project. This is the first patent granted around the CAN03 antibody and thereby of high importance to Cantargia”, Göran Forsberg, Cantargia’s CEO says.
For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
This constitutes information that Cantargia AB is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on 1 October 2018, at 8:30 a.m.
Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing antibody-based treatments for life-threatening diseases. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor accessory protein (IL1RAP) in leukemic stem cells. Subsequent research has also identified IL1RAP in many other forms of cancer. The company’s main project, the CAN04 (nidanilimab) antibody targeted against IL1RAP, is being studied in the CANFOUR clinical phase I/IIa study, where the primary focus is on non-small cell lung cancer and pancreatic cancer. CAN04 (nidanilimab) has two modes of action: it blocks the function of IL1RAP and stimulates the immune system to destroy tumour cells. Cantargia’s second project, currently in the research phase, is aimed at developing an IL1RAP-binding antibody that is optimised for treatment of autoimmune and inflammatory diseases.
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at http://www.cantargia.com.